Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (1065)	10/26/2001 10:23:31 AM
From: jayhawk969	Respond to of 1475

Stuart, Thanks for posting this article. Long but very interesting read. Too bad Osiris is privately held. I would love to have a part of this. This article would appear to have significant impact on BTRN. 1. Use of adult or embryonic stemcells to repair rather than replace organs would be a much simpler approach than xenotransplants or the alloimmune program. 2. If I recall correctly BTRN Australian stemcell investment is working with adult stemcells as well. What information do we have as to their specific programs and progress? I really like what I read about Osiris, maybe we can get KDUS to invest its 25 million<g>.